Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2024

16-01-2024 | Carcinoid Tumor | Gastrointestinal Oncology

Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis

Authors: Belinda H. McCully, PhD, Kaiya Kozuma, BS, SuEllen Pommier, PhD, Rodney F. Pommier, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Login to get access

Abstract

Background

Intraoperative carcinoid crisis is typically sudden onset of profound hypotension during operations on patients with neuroendocrine tumors. The crisis was thought to be due to massive release of hormones, and perioperative octreotide was recommended as a prophylaxis against the crisis and as first-line treatment. Recent studies show that octreotide does not prevent the crisis and that no massive release of hormones occurs. Therefore, the authors hypothesized that octreotide is not effective for treating the crisis.

Methods

A prospective carcinoid anesthesia database was analyzed for occurrences of crisis. Outcomes were compared between protocols when first-line therapy was bolus octreotide and when it was vasopressors without octreotide. Significance was determined by Student’s t test, the Mann-Whitney U test, and Fisher’s exact test.

Results

Among operations performed with octreotide as first-line treatment (n = 150), crisis occurred for 45 (30 %) patients, the median crisis duration was 6 min, 12 (27 %) patients had crises longer than 10 min, 42 patients (93 %) required subsequent vasopressor administration to resolve the crisis, and 3 (2 %) operations were aborted. Among operations performed with vasopressors as the first-line treatment (n = 195), crisis occurred for 49 (25 %) patients (p = 0.31), the median crisis duration was 3 min (p < 0.001), and no crisis lasted longer than 10 min (p = 0.001). Patients treated with vasopressors were less likely to have multiple crises and had a shorter total time in crisis, a shorter anesthesia time, and no aborted operations (p < 0.05 for all).

Conclusions

First-line octreotide was ineffective treatment for carcinoid crisis, with patients requiring vasopressors to resolve the crisis, and many crises lasting longer than 10 min. First-line vasopressor treatment resulted in significantly shorter crisis durations, fewer crises and aborted operations, and shorter anesthesia times. Vasopressors should be used as first-line treatment for intraoperative crisis, and treatment guidelines should be changed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Magabe PC, Bloom AL. Sudden death from carcinoid crisis during image-guided biopsy of a lung mass. J Vasc Interv Radiol. 2014;25:484–7.CrossRefPubMed Magabe PC, Bloom AL. Sudden death from carcinoid crisis during image-guided biopsy of a lung mass. J Vasc Interv Radiol. 2014;25:484–7.CrossRefPubMed
2.
go back to reference Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753–66.CrossRefPubMed Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39:753–66.CrossRefPubMed
3.
go back to reference Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.CrossRefPubMed Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.CrossRefPubMed
4.
go back to reference Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.CrossRefPubMed Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6–32.CrossRefPubMed
5.
go back to reference Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313:1229–30.CrossRefPubMed Kvols LK, Martin JK, Marsh HM, Moertel CG. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med. 1985;313:1229–30.CrossRefPubMed
6.
go back to reference Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001;87:447–52.CrossRefPubMed Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001;87:447–52.CrossRefPubMed
7.
go back to reference Condron ME, Jameson NE, Limbach KE, et al. A prospective study of the pathophysiology of carcinoid crisis. Surgery. 2019;165:158–65.CrossRefPubMed Condron ME, Jameson NE, Limbach KE, et al. A prospective study of the pathophysiology of carcinoid crisis. Surgery. 2019;165:158–65.CrossRefPubMed
8.
go back to reference Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159:358–65.CrossRefPubMed Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159:358–65.CrossRefPubMed
9.
go back to reference Kwon DH, Paciorek A, Mulvey CK, et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas. 2019;48:496–503.CrossRefPubMed Kwon DH, Paciorek A, Mulvey CK, et al. Periprocedural management of patients undergoing liver resection or embolotherapy for neuroendocrine tumor metastases. Pancreas. 2019;48:496–503.CrossRefPubMed
10.
go back to reference Massimino K, Harrskog O, Pommier S, Pommier R. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013;107:842–6.CrossRefPubMed Massimino K, Harrskog O, Pommier S, Pommier R. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. J Surg Oncol. 2013;107:842–6.CrossRefPubMed
11.
go back to reference Guo LJ, Tang CW. Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev. 2014;15:6679–83.CrossRefPubMed Guo LJ, Tang CW. Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev. 2014;15:6679–83.CrossRefPubMed
13.
go back to reference Wonn SM, Ratzlaff AN, Pommier SJ, McCully BH, Pommier RF. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery. 2022;171:88–93.CrossRefPubMed Wonn SM, Ratzlaff AN, Pommier SJ, McCully BH, Pommier RF. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery. 2022;171:88–93.CrossRefPubMed
14.
go back to reference Limbach KE, Condron ME, Bingham AE, Pommier SJ, Pommier RF. Beta-adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumor. Am J Surg. 2019;217:932–6.CrossRefPubMed Limbach KE, Condron ME, Bingham AE, Pommier SJ, Pommier RF. Beta-adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumor. Am J Surg. 2019;217:932–6.CrossRefPubMed
15.
go back to reference Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation. 1991;84:168–76.CrossRefPubMed Hoeldtke RD, Davis KM, Joseph J, Gonzales R, Panidis IP, Friedman AC. Hemodynamic effects of octreotide in patients with autonomic neuropathy. Circulation. 1991;84:168–76.CrossRefPubMed
16.
go back to reference Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001;120:975–83.CrossRefPubMed Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology. 2001;120:975–83.CrossRefPubMed
Metadata
Title
Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis
Authors
Belinda H. McCully, PhD
Kaiya Kozuma, BS
SuEllen Pommier, PhD
Rodney F. Pommier, MD
Publication date
16-01-2024
Publisher
Springer International Publishing
Keyword
Carcinoid Tumor
Published in
Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14876-4

Other articles of this Issue 5/2024

Annals of Surgical Oncology 5/2024 Go to the issue